Capricor Therapeutics, Inc. Tech Stack
Cell and exosome therapeutics for rare diseases, scaling CGMP manufacturing
Capricor is a publicly traded biotech focused on cell and exosome-based therapies for rare diseases, with lead programs in Duchenne muscular dystrophy and infectious disease. The hiring mix—dominated by manufacturing (14), ops (8), and quality (6) roles—reflects a company transitioning from clinical development to commercial-scale production. Active projects center on GMP compliance, process optimization, and technology transfer into CGMP manufacturing, while pain points cluster around yield improvement and deviation management, indicating capacity and consistency challenges in scaling from bench to clinic to manufacturing.
Tech Stack 13 technologies
What Capricor Therapeutics, Inc. Is Building
◆Challenges
- Gmp compliance
- Increasing yield
- Deviation and capa management
- Cgmp compliance challenges
- Ensuring compliance with cgmp
- Establishing medical affairs function
- Audit readiness
- Material shortages
- Shipping demands
- Bridging clinical development with commercialization readiness
▲Active Projects
- Continuous improvement of csv processes
- Sop development for material handling
- Optimize in vivo research practices
- Technology transfer into cgmp manufacturing
- Develop new animal models
- Packaging and label validation
- Real-world evidence initiatives
- Gmp system compliance mapping
- Evaluate new technologies and platforms
- Comparability assessment for process changes
Hiring Activity
Department
Seniority
Notable leadership hires: Pharmacovigilance Director, Biostatistics Director
